

## Datasheet: MCA749F

**BATCH NUMBER 159779**

<b>Description:</b>	MOUSE ANTI GUINEA PIG CD4:FITC
<b>Specificity:</b>	CD4
<b>Format:</b>	FITC
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	CT7
<b>Isotype:</b>	IgG1
<b>Quantity:</b>	100 TESTS

### Product Details

#### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			Neat - 1/10

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

<b>Target Species</b>	Guinea Pig		
<b>Product Form</b>	Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid		
<b>Max Ex/Em</b>	<b>Fluorophore</b>	<b>Excitation Max (nm)</b>	<b>Emission Max (nm)</b>
	FITC	490	525
<b>Preparation</b>	Purified IgG prepared by affinity chromatography on Protein G.		
<b>Buffer Solution</b>	Phosphate buffered saline		
<b>Preservative</b>	0.09% Sodium Azide		
<b>Stabilisers</b>	1% Bovine Serum Albumin		
<b>Approx. Protein Concentrations</b>	IgG concentration 0.1 mg/ml		

<b>Immunogen</b>	Guinea pig peritoneal T-cells.
<b>RRID</b>	AB_322605
<b>Fusion Partners</b>	Spleen cells from immunised BALB/c mice were fused with cells of the X63.Ag8.653 mouse myeloma cell line.
<b>Specificity</b>	<b>Mouse anti Guinea Pig CD4 antibody, clone CT7</b> recognizes the CD4 antigen present on T Helper/Inducer lymphocytes.
<b>Flow Cytometry</b>	Use 10ul of the suggested working dilution to label 10 <sup>6</sup> cells or 100ul whole Guinea Pig peripheral blood.
<b>References</b>	<ol style="list-style-type: none"> <li>1. Tan, B.T. <i>et al.</i> (1985) Production of monoclonal antibodies defining guinea pig T-cell surface markers and a strain 13 Ia-like antigen: the value of immunohistological screening. <a href="#">Hybridoma. 4 (2): 115-24.</a></li> <li>2. Baker, D. <i>et al.</i> (1987) Changes in lymphocyte subsets after treatment with cyclophosphamide and during the development of contact sensitivity in the guinea pig. <a href="#">Int J Immunopharmacol. 9 (2): 175-83.</a></li> <li>3. Liversidge, J. &amp; Forrester, J.V. (1988) Experimental autoimmune uveitis (EAU): immunophenotypic analysis of inflammatory cells in chorio retinal lesions. <a href="#">Curr Eye Res. 7 (12): 1231-41.</a></li> <li>4. Steerenberg, P.A. <i>et al.</i> (1991) Tumour rejection after adoptive transfer of line-10-immune spleen cells is mediated by two T cell subpopulations. <a href="#">Cancer Immunol Immunother. 34 (2): 103-10.</a></li> <li>5. Debout, C. <i>et al.</i> (1991) The Kurloff cell in estrogenized guinea pigs as a CT7+ 8BE6-CT6- MR-1- CT10- IgM- lymphocyte with natural killer activity. <a href="#">Nat Immun Cell Growth Regul. 10 (6): 327-35.</a></li> <li>6. Shang, S. <i>et al.</i> (2011) Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs. <a href="#">Antimicrob Agents Chemother. 55 (1): 124-31.</a></li> <li>7. Lacy, H.M. <i>et al.</i> (2011) Essential role for neutrophils in pathogenesis and adaptive immunity in <i>Chlamydia caviae</i> ocular infections. <a href="#">Infect Immun. 79 (5): 1889-97.</a></li> <li>8. Komori, T. <i>et al.</i> (2011) A Microbial Glycolipid Functions as a New Class of Target Antigen for Delayed-type Hypersensitivity. <a href="#">J Biol Chem. 286: 16800-6.</a></li> <li>9. Jeevan, A. <i>et al.</i> (2003) Differential expression of gamma interferon mRNA induced by attenuated and virulent Mycobacterium tuberculosis in guinea pig cells after <i>Mycobacterium bovis</i> BCG vaccination. <a href="#">Infect Immun. 71: 354-64.</a></li> <li>10. Schleiss, M.R. <i>et al.</i> (2007) Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. <a href="#">J Infect Dis. 195: 789-98.</a></li> <li>11. Turner, O.C. <i>et al.</i> (2003) Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with <i>Mycobacterium tuberculosis</i>. <a href="#">Infect Immun. 71: 864-71.</a></li> <li>12. Wang, Y. <i>et al.</i> (2010) Local host response to chlamydial urethral infection in male guinea pigs. <a href="#">Infect Immun. 78: 1670-81.</a></li> <li>13. Mishra, N.C. <i>et al.</i> (2010) Sulfur mustard induces immune sensitization in hairless guinea pigs. <a href="#">Int Immunopharmacol. 10: 193-9.</a></li> </ol>

14. Hiromatsu, K. *et al.* (2002) Induction of CD1-restricted immune responses in guinea pigs by immunization with mycobacterial lipid antigens. [J Immunol. 169: 330-9.](#)
15. Dascher, C.C. *et al.* (1999) Conservation of a CD1 multigene family in the guinea pig. [J Immunol. 163: 5478-88.](#)
16. Rousseau, C. *et al.* (2003) Sulfolipid Deficiency Does Not Affect the Virulence of *Mycobacterium tuberculosis* H37Rv in Mice and Guinea Pigs [Infect Immun. 71: 4684-90.](#)
17. Kramp, J.C. *et al.* (2011) The *in vivo* immunomodulatory effect of recombinant tumour necrosis factor-alpha in guinea pigs vaccinated with *Mycobacterium bovis* bacille Calmette-Guérin. [Clin Exp Immunol. 165: 110-20.](#)
18. Chitano, P. *et al.* (2014) Ovalbumin sensitization of guinea pig at birth prevents the ontogenetic decrease in airway smooth muscle responsiveness. [Physiol Rep. 2 \(12\)Dec 11 \[Epub ahead of print\].](#)
19. Gupta, A. *et al.* (2012) Efficacy of *Mycobacterium indicus pranii* immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung. [PLoS One. 7 \(7\): e39215.](#)
20. Podell, B.K. *et al.* (2014) Increased severity of tuberculosis in Guinea pigs with type 2 diabetes: a model of diabetes-tuberculosis comorbidity. [Am J Pathol. 184 \(4\): 1104-18.](#)
21. Shang, S. *et al.* (2012) Drug treatment combined with BCG vaccination reduces disease reactivation in guinea pigs infected with *Mycobacterium tuberculosis*. [Vaccine. 30 \(9\): 1572-82.](#)
22. Yang H *et al.* (2011) Three protein cocktails mediate delayed-type hypersensitivity responses indistinguishable from that elicited by purified protein derivative in the guinea pig model of *Mycobacterium tuberculosis* infection. [Infect Immun. 79 \(2\): 716-23.](#)
23. Jeevan A *et al.* (2013) Guinea pig skin, a model for epidermal cellular and molecular changes induced by UVR *in vivo* and *in vitro*: effects on *Mycobacterium bovis* Bacillus Calmette-Guérin vaccination. [Photochem Photobiol. 89 \(1\): 189-98.](#)
24. Miszczyk, E. *et al.* (2014) Antigen-specific lymphocyte proliferation as a marker of immune response in guinea pigs with sustained *Helicobacter pylori* infection. [Acta Biochim Pol. 61 \(2\): 295-303.](#)

<b>Storage</b>	<p>This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.</p> <p>Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.</p>
<b>Guarantee</b>	12 months from date of despatch
<b>Health And Safety Information</b>	<p>Material Safety Datasheet documentation #10041 available at: <a href="https://www.bio-rad-antibodies.com/SDS/MCA749F">https://www.bio-rad-antibodies.com/SDS/MCA749F</a></p> <p>10041</p>
<b>Regulatory</b>	For research purposes only

## Related Products

## Recommended Negative Controls

### MOUSE IgG1 NEGATIVE CONTROL:FITC (MCA928F)

**North & South** Tel: +1 800 265 7376

**America** Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://bio-rad-antibodies.com/datasheets)

'M384632:210513'

**Printed on 23 Nov 2023**

---

© 2023 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)